The rapamycin analog, ridaforolimus, has demonstrated potent anti-proliferative effects in cancer treatment, and it currently is being evaluated in a range of clinical cancer studies. Ridaforolimus is an extremely lipophilic compound with limited aqueous solubility, which may benefit from formulation with polymeric micelles. Herein, we report the encapsulation of ridaforolimus in 1,2-distearoyl- sn-glycero-3-phosphoethanolamine- N-methoxy-poly(ethylene glycol 2000) (DSPE-PEG 2000) via a solvent extraction technique. Micelle loading greatly improved the solubility of ridaforolimus by approximately 40 times from 200 μg/mL to 8.9 mg/mL. The diameters of the drug-loaded micelles were 33 ± 15 nm indicating they are of appropriate size to accumulate within the tumor site via the enhanced permeability and retention (EPR) effect. The DSPE-PEG 2000 micelle formulation was dosed intravenously to rats at 10 mg/kg and compared to a control of ridaforolimus in ethanol/PEG 400. The micelle significantly increased the half-life of ridaforolimus by 170% and decreased the clearance by 58%, which is consistent with improved retention of the drug in the plasma by the micelle formulation.
References
[1]
Yuan, R.; Kay, A.; Berg, W.J.; Lebwohl, D. Targeting tumorigenesis: Development and use of mTOR inhibitors in cancer therapy. J. Hematol. Oncol. 2009, 2, 45, doi:10.1186/1756-8722-2-45.
[2]
Mita, M.; Sankhala, K.; Abdel-Karim, I.; Mita, A.; Giles, F. Deforolimus (ap23573) a novel mtor inhibitor in clinical development. Expert Opin. Investig. Drugs 2008, 17, 1947–1954, doi:10.1517/13543780802556485.
[3]
Hartford, C.M.; Desai, A.A.; Janisch, L.; Karrison, T.; Rivera, V.M.; Berk, L.; Loewy, J.W.; Kindler, H.; Stadler, W.M.; Knowles, H.L. et al. A phase i trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin. Cancer Res. 2009, 15, 1428–1434.
[4]
Dancey, J.E. Therapeutic targets: Mtor and related pathways. Cancer Biol. Ther. 2006, 5, 1065–1073, doi:10.4161/cbt.5.9.3175.
[5]
Yanez, J.A.; Forrest, M.L.; Ohgami, Y.; Kwon, G.S.; Davies, N.M. Pharmacometrics and delivery of novel nanoformulated peg-b-poly(epsilon-caprolactone) micelles of rapamycin. Cancer Chemother. Pharma. 2008, 61, 133–144.
[6]
Dancey, J. Mtor signaling and drug development in cancer. Nat. Rev. Clin. Oncol. 2010, 7, 209–219, doi:10.1038/nrclinonc.2010.21.
[7]
Rivera, V.M.; Squillace, R.M.; Miller, D.; Berk, L.; Wardwell, S.D.; Ning, Y.; Pollock, R.; Narasimhan, N.I.; Iuliucci, J.D.; Wang, F. et al. Ridaforolimus (ap23573; mk-8669), a potent mtor inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol. Cancer Ther. 2011, 10, 1059–1071.
[8]
Croy, S.R.; Kwon, G.S. Polymeric micelles for drug delivery. Curr. Pharm. Des. 2006, 12, 4669–4684, doi:10.2174/138161206779026245.
[9]
Xiong, M.P.; Yanez, J.A.; Remsberg, C.M.; Ohgami, Y.; Kwon, G.S.; Davies, N.M.; Forrest, M.L. Formulation of a geldanamycin prodrug in mpeg-b-pcl micelles greatly enhances tolerability and pharmacokinetics in rats. J. Control. Release 2008, 129, 33–40, doi:10.1016/j.jconrel.2008.03.015.
[10]
Adams, M.L.; Lavasanifar, A.; Kwon, G.S. Amphiphilic block copolymers for drug delivery. J. Pharm. Sci. 2003, 92, 1343–1355, doi:10.1002/jps.10397.
[11]
Li, S.D.; Huang, L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 2008, 5, 496–504, doi:10.1021/mp800049w.
Forrest, M.L.; Won, C.Y.; Malick, A.W.; Kwon, G.S. In vitro release of the mtor inhibitor rapamycin from poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles. J. Control. Release 2006, 110, 370–377, doi:10.1016/j.jconrel.2005.10.008.
[14]
Bogusz, M.J.; Enazi, E.A.; Hassan, H.; Abdel-Jawaad, J.; Ruwaily, J.A.; Tufail, M.A. Simultaneous lc-ms-ms determination of cyclosporine a, tacrolimus, and sirolimus in whole blood as well as mycophenolic acid in plasma using common pretreatment procedure. J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 2007, 850, 471–480, doi:10.1016/j.jchromb.2006.12.048.
[15]
Poquette, M.A.; Lensmeyer, G.L.; Doran, T.C. Effective use of liquid chromatography-mass spectrometry (lc/ms) in the routine clinical laboratory for monitoring sirolimus, tacrolimus, and cyclosporine. Ther. Drug Monit. 2005, 27, 144–150, doi:10.1097/01.ftd.0000148451.35811.74.
[16]
Gibaldi, M.; Perrier, D. Pharmacokinetics, 2nd ed.; Informa Healthcare Inc.: New York, NY, USA, 2006.
